 T-Lymphocytes, Regulatory
"T-Lymphocytes, Regulatory" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
| Descriptor ID |
D050378
|
| MeSH Number(s) |
A11.118.637.555.567.550.500.700 A11.118.637.555.567.569.200.700 A11.118.637.555.567.569.500.700 A15.145.229.637.555.567.550.500.700 A15.145.229.637.555.567.569.200.700 A15.145.229.637.555.567.569.500.700 A15.382.490.555.567.550.500.700 A15.382.490.555.567.569.200.700 A15.382.490.555.567.569.500.700
|
| Concept/Terms |
T-Lymphocytes, Regulatory- T-Lymphocytes, Regulatory
- T Lymphocytes, Regulatory
- Regulatory T-Lymphocytes
- Regulatory T Lymphocytes
- Regulatory T-Lymphocyte
- T-Lymphocyte, Regulatory
- Regulatory T-Cells
- Regulatory T Cells
- T-Cells, Regulatory
- T Cells, Regulatory
- Treg Cells
- Cell, Treg
- Cells, Treg
- Treg Cell
Th3 Cells- Th3 Cells
- Cell, Th3
- Cells, Th3
- Th3 Cell
Suppressor T-Lymphocytes, Naturally-Occurring- Suppressor T-Lymphocytes, Naturally-Occurring
- Naturally-Occurring Suppressor T-Lymphocyte
- Naturally-Occurring Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, Naturally Occurring
- Suppressor T-Lymphocyte, Naturally-Occurring
- Suppressor T-Cells, Naturally-Occurring
- Naturally-Occurring Suppressor T-Cell
- Naturally-Occurring Suppressor T-Cells
- Suppressor T Cells, Naturally Occurring
- Suppressor T-Cell, Naturally-Occurring
- T-Cell, Naturally-Occurring Suppressor
- T-Cells, Naturally-Occurring Suppressor
Tr1 Cells- Tr1 Cells
- Cell, Tr1
- Cells, Tr1
- Tr1 Cell
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Regulatory".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Regulatory [A11.118.637.555.567.550.500.700]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD4-Positive T-Lymphocytes [A11.118.637.555.567.569.200]
- T-Lymphocytes, Regulatory [A11.118.637.555.567.569.200.700]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Regulatory [A11.118.637.555.567.569.500.700]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Regulatory [A15.145.229.637.555.567.550.500.700]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD4-Positive T-Lymphocytes [A15.145.229.637.555.567.569.200]
- T-Lymphocytes, Regulatory [A15.145.229.637.555.567.569.200.700]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Regulatory [A15.145.229.637.555.567.569.500.700]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Regulatory [A15.382.490.555.567.550.500.700]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD4-Positive T-Lymphocytes [A15.382.490.555.567.569.200]
- T-Lymphocytes, Regulatory [A15.382.490.555.567.569.200.700]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Regulatory [A15.382.490.555.567.569.500.700]
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Regulatory".
This graph shows the total number of publications written about "T-Lymphocytes, Regulatory" by people in UAMS Profiles by year, and whether "T-Lymphocytes, Regulatory" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2022 | 2 | 0 | 2 | | 2021 | 2 | 1 | 3 | | 2018 | 2 | 1 | 3 | | 2016 | 3 | 2 | 5 | | 2015 | 0 | 2 | 2 | | 2014 | 0 | 2 | 2 | | 2013 | 2 | 0 | 2 | | 2012 | 4 | 1 | 5 | | 2011 | 5 | 3 | 8 | | 2010 | 1 | 1 | 2 | | 2009 | 2 | 3 | 5 | | 2008 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "T-Lymphocytes, Regulatory" by people in Profiles over the past ten years.
-
Blanco T, Nakagawa H, Musayeva A, Krauthammer M, Singh RB, Narimatsu A, Ge H, Shoushtari SI, Dana R. Acquired immunostimulatory phenotype of migratory CD103+ DCs promotes alloimmunity following corneal transplantation. JCI Insight. 2024 Oct 22; 9(20).
-
O'Neal KA, Zeltner SL, Foscue CL, Stumhofer JS. Bhlhe40 limits early IL-10 production from CD4+ T cells during Plasmodium yoelii 17X infection. Infect Immun. 2023 11 16; 91(11):e0036723.
-
Nakao T, Inomata T, Blanco T, Musayeva A, Tahvildari M, Amouzegar A, Yin J, Chauhan SK, Chen Y, Dana R. Amplified Natural Killer Cell Activity and Attenuated Regulatory T-cell Function Are Determinants for Corneal Alloimmunity in Very Young Mice. Transplantation. 2023 06 01; 107(6):1302-1310.
-
Lozano-Ojalvo D, Tyler SR, Aranda CJ, Wang J, Sicherer S, Sampson HA, Wood RA, Burks AW, Jones SM, Leung DYM, de Lafaille MC, Berin MC. Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans. Allergy. 2023 03; 78(3):697-713.
-
Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, Mokhtari Z, Tabares P, B?ckle D, Rasche L, Martin Kort?m K, Lutz MB, Einsele H, Brandl A, Beilhack A. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia. 2022 03; 36(3):790-800.
-
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 04 27; 5(8):2196-2215.
-
Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021 02 24; 12(1):1281.
-
van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018; 9:2134.
-
Hartley CP, Carrillo-Polanco LF, Rowan DJ, Hagen CE. Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation. Mod Pathol. 2018 10; 31(10):1619-1626.
-
Zuo M, Shen H, Yin J, Wang W, Zhang Y, Zhou DB, Zhang W. Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma. Leuk Res. 2018 07; 70:56-61.
-
Chlopik A, Selim MA, Peng Y, Wu CL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. Hum Pathol. 2018 03; 73:176-183.
-
Gurram B, Hammelev E, Syverson G, Haribhai D, Yan K, Simpson P, Salzman N, Verbsky JW. Intact Regulatory T-Cell Function but Defective Generation of IL-17A-Producing CD4+ T Cells in XIAP Deficiency. J Pediatr Gastroenterol Nutr. 2016 08; 63(2):218-25.
-
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
-
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother. 2016 06; 39(5):191-201.
-
Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73.
-
Haribhai D, Ziegelbauer J, Jia S, Upchurch K, Yan K, Schmitt EG, Salzman NH, Simpson P, Hessner MJ, Chatila TA, Williams CB. Alternatively Activated Macrophages Boost Induced Regulatory T and Th17 Cell Responses during Immunotherapy for Colitis. J Immunol. 2016 Apr 15; 196(8):3305-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|